Hannah Britz

Field of research

Physiologically based pharmacokinetic (PBPK) Modeling of drug-drug interactions

Curriculum vitae

Since 10/2017: Doctoral student Clinical Pharmacy, Saarland University, Saarbrücken

02/2016 – 09/2017: Research assistant Clinical Pharmacy, Saarland University, Saarbrücken

12/2015: Licensed as pharmacist

05/2015 – 11/2015: Diploma student Clinical Pharmacy, Saarland University, Saarbrücken

11/2014 – 04/2015: Practical year, Paracelsus Apotheke, Saarbrücken

03/2013 – 10/2013: Research assistant Clinical Pharmacy, Saarland University, Saarbrücken

04/2010 – 10/2014: Pharmacy studies, Saarland University, Saarbrücken

10/2009 – 03/2010: Chemistry studies, Saarland University, Saarbrücken

07/2009: Abitur, Albert-Schweitzer-Gymnasium, Dillingen

Publications

Manuscripts

Britz H, Hanke N, Taub ME, Wang T, Prasad B, Fernandez É, Stopfer P, Nock V, Lehr T. Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions. Pharm Res 2020;37:250.

Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically‐based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2020;9(6):322-331.

Kovar L, Selzer D, Britz H, Benowitz N, St. Helen G, Kohl Y, Bals R, Lehr T. Comprehensive parent-metabolite PBPK/PD modeling insights into nicotine replacement therapy strategies. Clin Pharmacokinet 2020;59(9):1119-1134.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019;8(5):296-307.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7(10):647-659.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Sachse R, Lehr T. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. Cancer Chemother Pharmacol. 2018;81(2):291-304.

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol. 2017;80:1013-1026.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, Midazolam, and Digoxin: Application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J. 2017;19(1):298-312.